Xultophy 100/3.6 (active ingredients: insulin degludec and liraglutide) subcutaneous injection Initial FDA Approval: 2016 Side Effect Update Date: May 28, 2025 Medication Description: Treats type 2 diabetes Updated Side Effects/Safety Information: A new warning section on Severe Gastrointestinal Adverse Reactions. An additional new warning about the risk of serious kidney injury caused by dehydration due to gastrointestinal adverse effects like diarrhea and vomiting
Additionally, diminished CD47 expression has been reported in RBCs from individuals with chronic CKD (Antonelou et al., 2011)
[xiv] Berk M, Copolov D, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, Ording-Jespersen S, Little J, Conus P, Cuenod M, Do KQ, Busha AI: N- acetyl cysteine as a glutathione precursor for schizophreniaa double-blind, randomized, placebo-controlled trial
This is why most medications delivered through standard transdermal patches are small, lipophilic compounds such as nicotine or certain hormones
Importantly, treatment efficacy against Candida biofilms is highly strain- and species-dependent (Gulati and Nobile, 2016